Yes Anavex did not met all endpoints as defined at the time of their Dec 22 fumbled topline presentation, when Anavex claimed they were met. That was always clear and is now established by Missling himself recently admitting that ADL was not significant.
Since then alternative ways of presenting the data from the P2b/3 have been used and may indeed be approvable. The EMA submission if/when finalised, submitted and validated may then in turn lead to approval. That outcome will not be known for another year or so.
Q: "Can alternative endpoints be selected after a drug trial is finished?" A: "Yes, some clinical trials have successfully changed endpoints after the trial has begun."
Be careful with the careless nonsense posted here, folks.
News 
Market Data 
Discover 
AI
